Skip to content
Health
Link copied to clipboard
Link copied to clipboard

These Wharton grads say they can use A.I. to predict the outcomes of drug trials. Chelsea Clinton is among their backers.

BioPhy says it can predict trial outcomes with 80% accuracy. Clinton's VC firm and others have invested $4.5 million.

Dave Latshaw II, left, and Steven Truong are among the founders of BioPhy, a Philadelphia-based startup that uses artificial intelligence to predict clinical trial outcomes.
Dave Latshaw II, left, and Steven Truong are among the founders of BioPhy, a Philadelphia-based startup that uses artificial intelligence to predict clinical trial outcomes.Read moreBioPhy
    by Tom Avril
    Published